Back to Search
Start Over
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
- Source :
- Blood cancer journal, vol 12, iss 4, BLOOD CANCER JOURNAL, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Publication Year :
- 2022
-
Abstract
- Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
- Subjects :
- Myeloid
Leukemia, Myeloid, Acute / etiology
Cytarabine / therapeutic use
Oncology and Carcinogenesis
EUROPEAN-ORGANIZATION
RISK MYELODYSPLASTIC SYNDROME
Acute
Cardiorespiratory Medicine and Haematology
Bridged Bicyclo Compounds
Rare Diseases
QUALITY-OF-LIFE
Clinical Research
SUPPORTIVE CARE
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
REPORTED OUTCOMES
ELDERLY-PATIENTS
Fatigue
Cancer
Sulfonamides
Leukemia
OLDER PATIENTS
Heterocyclic
Cytarabine
Hematology
RANDOMIZED PHASE-III
Bridged Bicyclo Compounds, Heterocyclic
CONTROLLED-TRIALS
LOW-DOSE CYTARABINE
Leukemia, Myeloid, Acute
Fatigue / etiology
Oncology
Quality of Life
Leukemia, Myeloid, Acute / drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 20445385
- Database :
- OpenAIRE
- Journal :
- Blood cancer journal, vol 12, iss 4, BLOOD CANCER JOURNAL, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Accession number :
- edsair.doi.dedup.....8bcf3b9e9e68cdfa7fbed5e1e2969318